Randomised, Double-blind, Placebo-controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses of BI 685509 Over 28 Days in Male and Female Patients With Diabetic Nephropathy
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs BI 685509 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Oct 2017 Status changed from not yet recruiting to recruiting.
- 02 Oct 2017 Planned initiation date changed from 25 Sep 2017 to 17 Oct 2017.
- 21 Aug 2017 Planned End Date changed from 23 May 2018 to 13 Aug 2018.